SlidesetHIVInternational Workshop on HIV & Women 2020U = U Applies to Women! 2- Lena Serghides, PhDView Slideset
LSLena SerghidesPhDSlidesetHIVInternational Workshop on HIV & Women 2020U = U Applies to Women! - Lena Serghides, PhDView Slideset
SlidesetHIVInternational Workshop on HIV & Women 2020U = U Applies to Women! - Natella Rakhmanina, MD, PhD, FAAP, AAHIVView Slideset
NRNatella RakhmaninaMD, PhD, FAAP, FCP, AAHIVSSlidesetHIVInternational Workshop on HIV & Women 2020U=U does apply to women! - Natella Rakhmanina, MD, PhDView Slideset
AbstractHIVInternational Workshop on HIV & Women 2020Outcomes following prenatal exposure to Dolutegravir: the Dolomite - EPPICC Study - Claire Thorne, BA, MSc, PhDView Abstract
SlidesetHIVInternational Workshop on HIV & Women 2020Women Living with HIV and Research - Polly ClaydenView Slideset
SlidesetHIVInternational Workshop on HIV & Women 2020Women and HIV - Mental Health Considerations - Lorraine Sherr, BA, DipClinPsych, PhDView Slideset
SlidesetHIVInternational Workshop on HIV & Women 2020Women and Co-mordibities - Judith Currier, MD, MSCView Slideset
SlidesetHIVInternational Workshop on HIV & Women 2020Prevention Options for Women - Ariane van der Straten, PhD, MPHView Slideset
SlidesetHIVInternational Workshop on HIV & Women 2020Successes and Challenges Over the Last Decade in Research on Prevention of Mother-to-Child HIV Transmission - Lynne Mofenson, MDView Slideset
SlidesetHIVInternational Workshop on HIV & Women 2020ART and Women The Last Decade Successes and Challenges - Sharon Walmsley, FRCPC, MD, MSCView Slideset
VideoHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020A Phase 3, Open-label, Dose Escalation study to determine the pharmacokinetics of Atazanavir administered with RIfampicin to HIV positive adults on sEcond-line ART regimen with suppressed HIV-1 viral load (DERIVE): Scheduled Interim AnalysisView Video
